Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients

Diabetes, Obesity and Metabolism

Volumn 21, Issue 6, 2019, Pages 1498-1501

  Suliman, Mohamed ^a   Buckley, Adam ^a   Al Tikriti, Alia ^a   Tan, Tricia ^a   le Roux, Carel W ^a,b   Lessan, Nader ^a   Barakat, Maha ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

antiobesity drug; bariatric surgery; liraglutide

Indexed keywords

LIRAGLUTIDE; ANTIOBESITY AGENT;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARAB; ARTICLE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; BODY WEIGHT LOSS; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PATIENT CARE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SURGICAL PATIENT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; DRUG EFFECT; MIDDLE AGED;

ADULT; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; FEMALE; HUMANS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 85063376982     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13672     Document Type: Article

References (15)

1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13-27.
2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Nutr. 2014;63:2985-3023.
3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342-362.
4. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-1451.
5. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687-699.
6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
7. Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40:1310-1319.
8. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399-1409.
9. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424-2434.
10. Fujioka K, O'Neil PM, Davies M, et al. Early weight loss with Liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016;24:2278-2288.
11. Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13:491-500.
12. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794-797.
13. Liu Y, Tian Q, Yang J, Wang H, Hong T. Lack of pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of four cardiovascular outcome trials. Diabetes Metab Res Rev. 2018;34:e3061.
14. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723-730.
15. Wilding J. Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. Clin Obes. 2018;8:211-225.